Icosavax Announces Positive Topline Interim Phase 1 Results

–  IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – –  IVX-A12 was generally well tolerated with no...

Related Keywords

United States ,Jessica Yingling ,Adam Simpson ,Niranjan Kanesa Thasan ,Laurence Watts ,Nasdaq ,Exchange Commission ,University Of Washington ,Little Dog Communications Inc ,Institute For Protein Design ,Icosavax Inc ,Gilmartin Group ,Chief Executive Officer ,Chief Medical Officer ,Protein Design ,Private Securities Litigation Reform Act ,Nasdaq Icvx ,Icosavax ,Nc ,Nitgens ,Biotechnology ,Infectious Diseases ,Metapneumovirus ,Respiratory Syncytial Virus ,Vaccine ,